Clinical opinionOncologyRisk assessment to guide the prevention of cervical cancer
Section snippets
Background
Traditionally, the Papanicolaou smear or other cytologic method has been used as the primary test for cervical cancer screening programs. A positive cytologic result led to colposcopic evaluation and directed biopsy of apparent lesions. In turn, a biopsy diagnosed as CIN2 or worse (CIN2 or greater), or sometimes CIN1, led to treatment. Repetition of the cytology/colposcopy-based program has led to substantial decreases in cervical cancer rates in countries that have sufficient resources to
Risk Stratification
The concept of risk stratification (distinguishing the few women at risk from the many who are not at risk) is the principle underlying any screening test. With regard to carcinogenic HPV DNA testing, finding carcinogenic types in cervical specimens does not provide a diagnosis of CIN3 or cancer; rather, it identifies a group of women among whom CIN3/cancer is more likely. Complementary tests may provide even more powerful risk stratification. For example, cytologically normal women who test
Risk Thresholds
Professional clinical societies and cancer prevention experts together will make the decisions as to the proper clinical responses to which risk levels, considering benefits as well as total cost, which includes financial and negative health consequences. It is worth discussing to what extent protocols versus individual clinician judgment should dictate which tests are used, when, and how they should be interpreted. In general, we believe, because screening is inherently a population-wide
The Importance of Context in Clinical Decisions
Context is another element that figures into the risk predicted by a particular set of clinical test results. A risk associated with a positive test, like a carcinogenic HPV DNA test or CIN2 biopsy, is situational. An illustrative example is as follows: young women who have recently become sexually active have a high prevalence of carcinogenic HPV but an extremely low prevalence of precancerous lesions. In fact, the positive predictive value of a carcinogenic HPV test is so low in these women
Final Comments
We emphasize that it is critical when accepting a risk-based model for cervical cancer prevention to acknowledge that a minimally acceptable risk of precancer should be defined to avoid the overscreening and overtreatment of women in an attempt to achieve the unachievable: perfect sensitivity prevention. In addition to the almost certain negative consequences of an overly aggressive cervical cancer prevention program, including the impact on fertility,21 the number of cancers spared in the
References (30)
- et al.
2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests
Am J Obstet Gynecol
(2007) - et al.
Clinical applications of HPV testing: a summary of meta-analyses
Vaccine
(2006) - et al.
Colposcopy at a crossroads
Am J Obstet Gynecol
(2006) - et al.
Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS)
Am J Obstet Gynecol
(2006) - et al.
Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy
Am J Obstet Gynecol
(2003) - et al.
Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis
Lancet
(2006) - et al.
The burden of HPV-related cancers
Vaccine
(2006) - et al.
Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence
Gynecol Oncol
(2005) - et al.
Risk of pre-cancer and follow-up management strategies for women with HPV-negative ASCUS
Obstet Gynecol
(2007) - et al.
Global cancer statistics, 2002
CA Cancer J Clin
(2005)
Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study
JAMA
A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations
Am J Obstet Gynecol
Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening
Obstet Gynecol
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice
J Natl Cancer Inst
Adding a test for human papillomavirus DNA to cervical-cancer screening
N Engl J Med
Cited by (148)
Preinvasive disease of the cervix
2023, DiSaia and Creasman Clinical Gynecologic OncologyBenefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program
2021, American Journal of Obstetrics and GynecologyPost-Colposcopy Management and Progression Predictors of Biopsy-Proven CIN1 in Women Under 25 Years
2019, Journal of Obstetrics and Gynaecology Canada
Cite this article as: Castle PE, Sideri M, Jeronimo J, et al. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007;197:356.e1-356.e6.
This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. The financial activities of P.E.C., J.J., D.S., and M.S. are monitored by the National Cancer Institute Ethics Office.